Proactive Investors - Run By Investors For Investors

CytoDyn files for fast-track designation for leronlimab in breast cancer treatment

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive Investors the biotechnology company filed an application with the FDA seeking fast-track designation for its injectable antibody leronlimab for patients with metastatic-triple negative breast cancer.

Pourhassan also commented on its HIV indication for leronlimab, commenting there is a large biological manufacturer willing to produce 'half a billion dollars worth' of the company's product by the end of 2020.

 
View full CYDY profile View Profile

CytoDyn Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use